SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference Mar 5, 2020
SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) Feb 13, 2020
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting Jan 8, 2020
SCYNEXIS Appoints Business Development Veteran Philippe Tinmouth to its Board of Directors Dec 16, 2019
SCYNEXIS Commends the CDC for the Recognition of Candida auris as a New "Urgent Threat" in its Updated Report on Antibiotic Resistance Threats in the United States Nov 14, 2019
SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303) Nov 7, 2019
